April 16, 2019 05:11 PM EDTUpdated 05:26 PM
People

Rev­enue plunges, stock takes a drub­bing, but Te­va CEO Kåre Schultz still grabs $32.5M in chart-top­ping com­pen­sa­tion

John Carroll

Editor & Founder

Te­va CEO Kåre Schultz hasn’t man­aged to turn the ship around at Te­va, but that didn’t stop him from be­com­ing the high­est paid Big Phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times